ANAB
ANAB
NASDAQ · Biotechnology

Anaptysbio Inc

$69.33
+2.37 (+3.54%)
As of May 10, 10:08 PM ET ·
Financial Highlights (FY 2026)
Revenue
243.55M
Net Income
-13,736,045
Gross Margin
Profit Margin
-5.6%
Rev Growth
+183.6%
D/E Ratio
7.43
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.0% 67.0%
Operating Margin 20.4% -113.3% 1.0% 1.3%
Profit Margin -5.6% -151.2% 1.1% 1.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 243.55M 82.73M 183.45M 146.61M
Gross Profit 122.96M 98.26M
Operating Income 49.73M -93,767,267 1.91M 1.85M
Net Income -13,736,045 -118,469,876 2.09M 1.41M
Gross Margin 67.0% 67.0%
Operating Margin 20.4% -113.3% 1.0% 1.3%
Profit Margin -5.6% -151.2% 1.1% 1.0%
Rev Growth +183.6% +13.1% +5.3% +16.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 889.14M 772.64M 219.73M 209.35M
Total Equity 119.64M 154.93M 894.48M 927.05M
D/E Ratio 7.43 4.99 0.25 0.23
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -27,000,389 -141,571,926 3.06M 2.67M
Free Cash Flow 1.04M 763.9K